With multiple clinical trials under way, it’s likely both a drug using Ac-225 and increased demand for the radioisotope are in the near future — and the U.S. Department of Energy wants to be ready. Since 2015, DOE’s Isotope Program has sponsored the Tri-Lab Effort to Provide Accelerator-produced Ac-225 for Radiotherapy. Thorium-232 targets are irradiated in proton accelerators at Los Alamos and Brookhaven national laboratories, then sent to ORNL for processing in hot cells dedicated to alpha radiation. The purpose: producing bigger batches, faster. In June, ORNL processed the largest batch of Ac-225 ever put in inventory.